Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,pembrolizumab,"First line persistent, recurrent or metastatic cervical cancer in addition to chemotherapy, for patients with a PD-L1 combined positive score of 1 or more, with bevacizumab",pembrolizumab (Keytruda),Recommended for decline,Hospital,Oncology Agents and Immunosuppressants
